Empagliflozin

Epallipazine is used in the treatment of 2 diabetic adults who have not achieved adequate glycemic control through diet and exercise to improve glycemic control. It should not be used to treat patients with type 1 Chemicalbook diabetes, patients with elevated ketones in the blood or urine (diabetic ketoacidosis), patients with severe kidney injury, end-stage kidney disease, and patients on dialysis. Net (Empagliflozin), according to Mr Column by boehringer ingelheim and eli lilly company joint development of a type 2 sodium glucose transporters together (SGLT - 2, sodium - dependentglucosecotransporterChemicalbook2) inhibitors. SGLT-2 inhibitors are a new type of hypoglycemic agents. They reduce the reabsorption of glucose by the kidney and increase the excretion of glucose in the urine by inhibiting the expression of SGLT-2, thus reducing the plasma glucose level. The hypoglycemic effect is independent of β cell function and insulin resistance.